Neoadjuvant chemotherapy is associated with improved disease‐free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Dustin L Dillon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Pancreaticoduodenectomy, Pancreatic Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: UCLA Health, Department of Surgery.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background and Objectives Neoadjuvant chemotherapy (NAC) is becoming favored for all pancreatic adenocarcinoma (PDAC). Patients with seemingly resectable disease infrequently still display vascular involvement intraoperatively. Outcomes following NAC versus upfront surgery in patients undergoing pancreaticoduodenectomy (PD) with vascular resection are unknown.
Methods
We performed a retrospective cohort study of PDAC patients who underwent PD with vascular resection between January 1, 2013, to December 31, 2020, within a single academic center. Clinicopathologic characteristics and disease‐free survival (DFS) were compared between NAC versus upfront surgery cohorts using the Kaplan–Meier estimate and Cox proportional‐hazards regression model.
Results
Eighty‐one patients who underwent PD with vascular resection for PDAC were included. Forty‐six patients (56%) received NAC. The NAC cohort more often had pathologic N0 status (47.8% vs. 8.6%, p < 0.001), had decreased vascular invasion (11% vs. 40%, p = 0.002), and completed chemotherapy (80% vs. 40%, p < 0.01). The NAC cohort demonstrated improved DFS (40.5 vs. 14.3 months, p = 0.007). In multivariable analysis, NAC remained independently associated with increased DFS (HR = 0.48, p = 0.02).
Conclusions
NAC was associated with improved clinicopathologic outcomes and DFS in PD with vascular resection. These findings demonstrate the advantage of NAC in PDAC patients undergoing PD with vascular resection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, California, USA.
- Department of Surgery, Division of Surgical Oncology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.
Förderung
- UCLA Health, Department of Surgery
Zitieren
APA
Dillon, D. L., Park, J. Y., Mederos, M. A., Seo, Y. J., King, J., Hines, J., Donahue, T., & Girgis, M. D. (2024). Neoadjuvant chemotherapy is associated with improved disease‐free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27674
Vancouver
Dillon DL, Park JY, Mederos MA, Seo YJ, King J, Hines J, et al. Neoadjuvant chemotherapy is associated with improved disease‐free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27674
BibTeX
@article{Dillon2024,
author = {Dillon, Dustin L and Park, Joon Y and Mederos, Michael A and Seo, Young-Ji and King, Jonathan and Hines, Joe and Donahue, Timothy and Girgis, Mark D},
title = {Neoadjuvant chemotherapy is associated with improved disease‐free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27674}
}
EUVIMED